Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. No formal trade talks are scheduled between the U.S. and China, but President Trump...
— New Safety and Tolerability Data to Be Presented From ALPINE Study of ARISTADA ® and INVEGA SUSTENNA ® in Patients With Schizophrenia — DUBLIN , May 22, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present new data f...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Retailers cap off the Q1 earnings season in style as Target (TGT), Best Buy (BBY), ...
DUBLIN , May 14, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson , will participate in a fireside chat at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 8:00 a.m. ET ( 1:00 p....
DUBLIN , May 13, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will present data from its mental health portfolio at the American Psychiatric Association (APA) Annual Meeting in San Francisco and the International Society for Pharmacoeconomics and Outco...
Active investment management wins again This is a classic example with Alkermes, plc ( ALKS ) of an investing strategy which turns the "risk-terror" of price "volatility" into the productive work of being alert and using the disciplines of a clearly-stated (and followed) portfolio manageme...
Gilead Sciences ( GILD ) - The company announced that a phase 3 NASH study for key asset selonsertib failed to meet its primary endpoint. Dubbed STELLAR-3, the trial was investigating the oral inhibitor of ASK1 in patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis. Th...
Alkermes plc (ALKS) Q1 2019 Earnings Conference Call April 25, 2019 8:30 A.M. ET Company Participants Sandy Coombs - Vice President, Investor Relations Jim Frates - Chief Financial Officer Craig Hopkinson - Chief Medical Officer Richard Pops - Chief Executive Officer Confere...
News, Short Squeeze, Breakout and More Instantly...
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Alkermes plc Reports Second Quarter 2024 Financial Results PR Newswire — Second Quarter Revenues of $399.1 Million — — Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income from C...
2024-07-22 10:45:03 ET Enbridge Inc (ENB) ENB is trading UP for the last 5 days, and it at trading at $36.59 with volume of 731,965 and a one day change of $0.05 (0.14%). Enbridge Inc has a 52-week low of 31.03 and a 52-week high of $38.36. The business's 50-day moving average price...